Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer
Background Clinical efficacy of aggressive end-of-life (EOL) chemotherapy remains unclear. Method Medical records of patients with advanced cancer between August 2011 and August 2016 were retrospectively analyzed. The primary endpoint was to identify prognostic factors at the last administration of...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical oncology 2019-04, Vol.24 (4), p.454-459 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 459 |
|---|---|
| container_issue | 4 |
| container_start_page | 454 |
| container_title | International journal of clinical oncology |
| container_volume | 24 |
| creator | Hiramoto, Shuji Tamaki, Tomoko Nagashima, Kengo Hori, Tetsuo Kikuchi, Ayako Yoshioka, Akira Inoue, Akira |
| description | Background
Clinical efficacy of aggressive end-of-life (EOL) chemotherapy remains unclear.
Method
Medical records of patients with advanced cancer between August 2011 and August 2016 were retrospectively analyzed. The primary endpoint was to identify prognostic factors at the last administration of chemotherapy. The secondary endpoint was to analyze the relationship between EOL symptoms and EOL treatment details.
Results
Among 300 evaluated patients, the number of patients who died within 14 and 30 days from the last administration of chemotherapy were 16 (5.3%) and 50 (16.7%), respectively. Multivariate analysis revealed that ECOG-PS (OR 3.698,
p
|
| doi_str_mv | 10.1007/s10147-018-1363-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2127660724</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2127091801</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-4c0c5912331ec99a34f2d99714810038b2246080e4074f0fc259af49aa2a46153</originalsourceid><addsrcrecordid>eNp1kE1rGzEQhkVoyPcP6KUIeulFyYykXa2OJaRNIZAcEshNyNqRvcFeudI6Jf8-cp02UOhpBPPMO6OHsY8I5whgLgoCaiMAO4GqVcLssSPUyghjjPxQ30qjsK1sDtlxKU8AaNpGHrBDBcqYrlFH7PEup_mYyjQEHn2YUi58GPnaTwONU-G_FolnCjQ8U89p7EWKYjlE4mFBqzQtKPv1C48pc98_-zFUKmxLPmX70S8Lnb3VE_bw7er-8lrc3H7_cfn1RgTdyknoAKGxKJVCCtZ6paPsrTWou_pF1c2k1C10QBqMjhCDbKyP2novvW6xUSfsyy53ndPPDZXJrYYSaLn0I6VNcRKlaVswUlf08z_oU9rksV73mwKLHWClcEeFnErJFN06DyufXxyC22p3O-2uandb7c7UmU9vyZvZivq_E388V0DugFJb45zy--r_p74Cw2uLXg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2127091801</pqid></control><display><type>article</type><title>Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Hiramoto, Shuji ; Tamaki, Tomoko ; Nagashima, Kengo ; Hori, Tetsuo ; Kikuchi, Ayako ; Yoshioka, Akira ; Inoue, Akira</creator><creatorcontrib>Hiramoto, Shuji ; Tamaki, Tomoko ; Nagashima, Kengo ; Hori, Tetsuo ; Kikuchi, Ayako ; Yoshioka, Akira ; Inoue, Akira</creatorcontrib><description>Background
Clinical efficacy of aggressive end-of-life (EOL) chemotherapy remains unclear.
Method
Medical records of patients with advanced cancer between August 2011 and August 2016 were retrospectively analyzed. The primary endpoint was to identify prognostic factors at the last administration of chemotherapy. The secondary endpoint was to analyze the relationship between EOL symptoms and EOL treatment details.
Results
Among 300 evaluated patients, the number of patients who died within 14 and 30 days from the last administration of chemotherapy were 16 (5.3%) and 50 (16.7%), respectively. Multivariate analysis revealed that ECOG-PS (OR 3.698,
p
< 0.001) and GPS2 (OR 3.791,
p
= 0.028) were significant prognostic factors. The MST of patients with both PS 2–4 and GPS2 (+) was 38 days, while that in patients with both PS 0–1 and GPS2 (−) was 134.5 days. The prevalence rate of nausea and vomiting (25.0%) and the mean hydration volume (0.50 L/day) in patients who died within 30 days from the chemotherapy was significantly higher than others (7.4%) (0.20 L/day).
Conclusion
ECOG-PS and GPS were significant prognostic factors for aggressive EOL chemotherapy. Information on these factors may aid clinical decision-making in terms of risk–benefit balance, particularly in patients with poor prognosis.</description><identifier>ISSN: 1341-9625</identifier><identifier>EISSN: 1437-7772</identifier><identifier>DOI: 10.1007/s10147-018-1363-7</identifier><identifier>PMID: 30377853</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Aged ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Cancer ; Cancer Research ; Chemotherapy ; Decision making ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Medical prognosis ; Medical records ; Medicine ; Medicine & Public Health ; Middle Aged ; Multivariate Analysis ; Nausea ; Nausea - chemically induced ; Neoplasms - drug therapy ; Neoplasms - mortality ; Neoplasms - therapy ; Oncology ; Original Article ; Patients ; Prognosis ; Retrospective Studies ; Surgical Oncology ; Terminal Care - methods ; Treatment Outcome ; Vomiting ; Vomiting - chemically induced</subject><ispartof>International journal of clinical oncology, 2019-04, Vol.24 (4), p.454-459</ispartof><rights>Japan Society of Clinical Oncology 2018</rights><rights>International Journal of Clinical Oncology is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-4c0c5912331ec99a34f2d99714810038b2246080e4074f0fc259af49aa2a46153</citedby><cites>FETCH-LOGICAL-c462t-4c0c5912331ec99a34f2d99714810038b2246080e4074f0fc259af49aa2a46153</cites><orcidid>0000-0002-3825-9443</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10147-018-1363-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10147-018-1363-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,778,782,27911,27912,41475,42544,51306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30377853$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hiramoto, Shuji</creatorcontrib><creatorcontrib>Tamaki, Tomoko</creatorcontrib><creatorcontrib>Nagashima, Kengo</creatorcontrib><creatorcontrib>Hori, Tetsuo</creatorcontrib><creatorcontrib>Kikuchi, Ayako</creatorcontrib><creatorcontrib>Yoshioka, Akira</creatorcontrib><creatorcontrib>Inoue, Akira</creatorcontrib><title>Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer</title><title>International journal of clinical oncology</title><addtitle>Int J Clin Oncol</addtitle><addtitle>Int J Clin Oncol</addtitle><description>Background
Clinical efficacy of aggressive end-of-life (EOL) chemotherapy remains unclear.
Method
Medical records of patients with advanced cancer between August 2011 and August 2016 were retrospectively analyzed. The primary endpoint was to identify prognostic factors at the last administration of chemotherapy. The secondary endpoint was to analyze the relationship between EOL symptoms and EOL treatment details.
Results
Among 300 evaluated patients, the number of patients who died within 14 and 30 days from the last administration of chemotherapy were 16 (5.3%) and 50 (16.7%), respectively. Multivariate analysis revealed that ECOG-PS (OR 3.698,
p
< 0.001) and GPS2 (OR 3.791,
p
= 0.028) were significant prognostic factors. The MST of patients with both PS 2–4 and GPS2 (+) was 38 days, while that in patients with both PS 0–1 and GPS2 (−) was 134.5 days. The prevalence rate of nausea and vomiting (25.0%) and the mean hydration volume (0.50 L/day) in patients who died within 30 days from the chemotherapy was significantly higher than others (7.4%) (0.20 L/day).
Conclusion
ECOG-PS and GPS were significant prognostic factors for aggressive EOL chemotherapy. Information on these factors may aid clinical decision-making in terms of risk–benefit balance, particularly in patients with poor prognosis.</description><subject>Aged</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Chemotherapy</subject><subject>Decision making</subject><subject>Female</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical records</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Nausea</subject><subject>Nausea - chemically induced</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - mortality</subject><subject>Neoplasms - therapy</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Surgical Oncology</subject><subject>Terminal Care - methods</subject><subject>Treatment Outcome</subject><subject>Vomiting</subject><subject>Vomiting - chemically induced</subject><issn>1341-9625</issn><issn>1437-7772</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kE1rGzEQhkVoyPcP6KUIeulFyYykXa2OJaRNIZAcEshNyNqRvcFeudI6Jf8-cp02UOhpBPPMO6OHsY8I5whgLgoCaiMAO4GqVcLssSPUyghjjPxQ30qjsK1sDtlxKU8AaNpGHrBDBcqYrlFH7PEup_mYyjQEHn2YUi58GPnaTwONU-G_FolnCjQ8U89p7EWKYjlE4mFBqzQtKPv1C48pc98_-zFUKmxLPmX70S8Lnb3VE_bw7er-8lrc3H7_cfn1RgTdyknoAKGxKJVCCtZ6paPsrTWou_pF1c2k1C10QBqMjhCDbKyP2novvW6xUSfsyy53ndPPDZXJrYYSaLn0I6VNcRKlaVswUlf08z_oU9rksV73mwKLHWClcEeFnErJFN06DyufXxyC22p3O-2uandb7c7UmU9vyZvZivq_E388V0DugFJb45zy--r_p74Cw2uLXg</recordid><startdate>20190401</startdate><enddate>20190401</enddate><creator>Hiramoto, Shuji</creator><creator>Tamaki, Tomoko</creator><creator>Nagashima, Kengo</creator><creator>Hori, Tetsuo</creator><creator>Kikuchi, Ayako</creator><creator>Yoshioka, Akira</creator><creator>Inoue, Akira</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3825-9443</orcidid></search><sort><creationdate>20190401</creationdate><title>Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer</title><author>Hiramoto, Shuji ; Tamaki, Tomoko ; Nagashima, Kengo ; Hori, Tetsuo ; Kikuchi, Ayako ; Yoshioka, Akira ; Inoue, Akira</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-4c0c5912331ec99a34f2d99714810038b2246080e4074f0fc259af49aa2a46153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Chemotherapy</topic><topic>Decision making</topic><topic>Female</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical records</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Nausea</topic><topic>Nausea - chemically induced</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - mortality</topic><topic>Neoplasms - therapy</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Surgical Oncology</topic><topic>Terminal Care - methods</topic><topic>Treatment Outcome</topic><topic>Vomiting</topic><topic>Vomiting - chemically induced</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hiramoto, Shuji</creatorcontrib><creatorcontrib>Tamaki, Tomoko</creatorcontrib><creatorcontrib>Nagashima, Kengo</creatorcontrib><creatorcontrib>Hori, Tetsuo</creatorcontrib><creatorcontrib>Kikuchi, Ayako</creatorcontrib><creatorcontrib>Yoshioka, Akira</creatorcontrib><creatorcontrib>Inoue, Akira</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hiramoto, Shuji</au><au>Tamaki, Tomoko</au><au>Nagashima, Kengo</au><au>Hori, Tetsuo</au><au>Kikuchi, Ayako</au><au>Yoshioka, Akira</au><au>Inoue, Akira</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer</atitle><jtitle>International journal of clinical oncology</jtitle><stitle>Int J Clin Oncol</stitle><addtitle>Int J Clin Oncol</addtitle><date>2019-04-01</date><risdate>2019</risdate><volume>24</volume><issue>4</issue><spage>454</spage><epage>459</epage><pages>454-459</pages><issn>1341-9625</issn><eissn>1437-7772</eissn><abstract>Background
Clinical efficacy of aggressive end-of-life (EOL) chemotherapy remains unclear.
Method
Medical records of patients with advanced cancer between August 2011 and August 2016 were retrospectively analyzed. The primary endpoint was to identify prognostic factors at the last administration of chemotherapy. The secondary endpoint was to analyze the relationship between EOL symptoms and EOL treatment details.
Results
Among 300 evaluated patients, the number of patients who died within 14 and 30 days from the last administration of chemotherapy were 16 (5.3%) and 50 (16.7%), respectively. Multivariate analysis revealed that ECOG-PS (OR 3.698,
p
< 0.001) and GPS2 (OR 3.791,
p
= 0.028) were significant prognostic factors. The MST of patients with both PS 2–4 and GPS2 (+) was 38 days, while that in patients with both PS 0–1 and GPS2 (−) was 134.5 days. The prevalence rate of nausea and vomiting (25.0%) and the mean hydration volume (0.50 L/day) in patients who died within 30 days from the chemotherapy was significantly higher than others (7.4%) (0.20 L/day).
Conclusion
ECOG-PS and GPS were significant prognostic factors for aggressive EOL chemotherapy. Information on these factors may aid clinical decision-making in terms of risk–benefit balance, particularly in patients with poor prognosis.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>30377853</pmid><doi>10.1007/s10147-018-1363-7</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-3825-9443</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-9625 |
| ispartof | International journal of clinical oncology, 2019-04, Vol.24 (4), p.454-459 |
| issn | 1341-9625 1437-7772 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2127660724 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Aged Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Cancer Cancer Research Chemotherapy Decision making Female Humans Kaplan-Meier Estimate Male Medical prognosis Medical records Medicine Medicine & Public Health Middle Aged Multivariate Analysis Nausea Nausea - chemically induced Neoplasms - drug therapy Neoplasms - mortality Neoplasms - therapy Oncology Original Article Patients Prognosis Retrospective Studies Surgical Oncology Terminal Care - methods Treatment Outcome Vomiting Vomiting - chemically induced |
| title | Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T23%3A24%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20factors%20in%20patients%20who%20received%20end-of-life%20chemotherapy%20for%20advanced%20cancer&rft.jtitle=International%20journal%20of%20clinical%20oncology&rft.au=Hiramoto,%20Shuji&rft.date=2019-04-01&rft.volume=24&rft.issue=4&rft.spage=454&rft.epage=459&rft.pages=454-459&rft.issn=1341-9625&rft.eissn=1437-7772&rft_id=info:doi/10.1007/s10147-018-1363-7&rft_dat=%3Cproquest_cross%3E2127091801%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2127091801&rft_id=info:pmid/30377853&rfr_iscdi=true |